CalciMedica Inc. announced the appointment of Alan Glicklich, M.D., to its Board of Directors, effective January 15, 2025. Dr. Glicklich brings more than 20 years of experience in the biotechnology industry, with a strong background in clinical development for inflammatory and immunologic diseases. His expertise is expected to be highly valuable as the company advances its lead candidate, Auxora.
Dr. Glicklich currently serves as Chief Medical Officer of Nuvig Therapeutics and previously held the same role at Chinook Therapeutics, where he designed and operationalized a successful Phase 3 registrational study for atrasentan in IgA nephropathy. His track record includes leading clinical development teams and managing regulatory processes for multiple early and late-stage programs. This experience is directly relevant to CalciMedica's strategic goals.
Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, stated that Dr. Glicklich's perspective will be extremely valuable as the company progresses Auxora towards a Phase 3 trial in acute pancreatitis and anticipates data from the KOURAGE trial in acute kidney injury. Dr. Glicklich expressed his impression of Auxora's data, noting its benefits in acute inflammatory diseases where organ failure is a significant cause of mortality.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.